Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DRM006
MIFTS: 66

Dermatitis

Categories: Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Dermatitis

About this section

MalaCards integrated aliases for Dermatitis:

Name: Dermatitis 12 55 44 15 73
Eczema 12 76 29 55 6 43 63 73
Inflammatory Dermatosis 73
Skin Inflammation 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Dermatitis

About this section
MedlinePlus : 43 Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause is not known. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Dermatitis, also known as eczema, is related to dermatitis herpetiformis and allergic contact dermatitis, and has symptoms including exanthema and pruritus. An important gene associated with Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Menthol and Zinc have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin.

PubMed Health : 63 About eczema: Eczema is a common, chronic, non-infectious skin condition. The main symptom of this inflammatory disease is a very itchy rash. It often affects children. In many cases eczema gets better as the years go by, and it may go away for a while or disappear altogether. Acute flare-ups can really affect quality of life. The itching can be especially bad, making it difficult to concentrate and sleep well. Some people are embarrassed if their rash is visible to others. By taking good care of your skin, using medication and avoiding irritants and other things that can trigger the eczema, it is usually possible to relieve the symptoms at least enough to live a fairly normal life.Eczema is sometimes also called "atopic eczema" or "atopic dermatitis."

Wikipedia : 76 Dermatitis, also known as eczema, is a group of diseases that results in inflammation of the skin. These... more...

Sources

Related Diseases for Dermatitis

About this section

Diseases related to Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)
# Related Disease Score Top Affiliating Genes
1 dermatitis herpetiformis 34.9 CCL11 IL31 IL4
2 allergic contact dermatitis 34.8 CCL17 FLG IL31 IL4
3 contact dermatitis 33.7 CCL17 CCL22 CCL27 FLG IL31 IL4
4 egg allergy 32.8 IGHE IL4
5 onchocerciasis 32.8 CCL11 IL13 IL4
6 bullous pemphigoid 32.7 CCL11 CCL17 DSG1
7 allergic rhinitis 32.7 CCL11 IGHE IL13 IL4
8 dermatitis, atopic 31.6 CCL11 CCL17 CCL22 CCL27 CMA1 FLG
9 food allergy 31.4 FLG IL13 IL4
10 asthma 31.1 CCL11 CCL17 CCL22 FLG IGHE IL13
11 rhinitis 31.1 CCL11 IGHE IL13 IL4
12 conjunctivitis 31.1 CCL11 IL13 IL4
13 atopic keratoconjunctivitis 30.8 CCL22 IGHE IL4
14 allergic conjunctivitis 30.7 CCL11 IL13 IL4
15 keratoconjunctivitis 30.7 CCL11 CCL17 IL13 IL4
16 psoriasis 30.6 CCL17 CCL22 CCL27 FLG IL13 IL4
17 lichen amyloidosis 30.5 IL31 IL31RA
18 schistosomiasis 30.5 IGHE IL13 IL4
19 peanut allergy 30.4 CCL22 FLG IGHE IL13
20 vernal keratoconjunctivitis 30.3 CCL11 IL13 IL4
21 latex allergy 30.3 FLG IGHE IL13 IL4
22 ige responsiveness, atopic 30.1 FLG IGHE IL13 IL4 TSLP
23 hypereosinophilic syndrome 30.1 CCL11 CCL17 IGHE IL13 IL4
24 blepharoconjunctivitis 30.0 CCL11 CMA1 IL4
25 strongyloidiasis 30.0 CCL11 IL13
26 allergic asthma 29.9 CCL11 CCL17 IGHE IL13 IL4 TSLP
27 blepharitis 29.8 CCL11 IL4
28 skin disease 29.7 CCL17 CCL27 DSG1 FLG IL13 IL31
29 ascaris lumbricoides infection 29.3 IL13 TSLP
30 chronic conjunctivitis 28.9 CCL11 CMA1 IL13 IL4 TSLP
31 irritant dermatitis 12.4
32 seborrheic dermatitis 12.4
33 seborrheic infantile dermatitis 12.3
34 dermatitis, atopic, 2 12.3
35 cercarial dermatitis 12.3
36 seborrhea-like dermatitis with psoriasiform elements 12.2
37 chronic actinic dermatitis 12.2
38 autoimmune progesterone dermatitis 12.2
39 photoallergic dermatitis 12.2
40 phototoxic dermatitis 12.2
41 contagious pustular dermatitis 12.1
42 dermatitis herpetiformis, familial 12.1
43 dermatitis, atopic, 3 12.1
44 immunodeficiency 11b with atopic dermatitis 12.1
45 interstitial granulomatous dermatitis with arthritis 12.1
46 microcephaly, congenital cataract, and psoriasiform dermatitis 12.1
47 dermatitis, atopic, 4 12.1
48 dermatitis, atopic, 5 12.1
49 dermatitis, atopic, 6 12.1
50 dermatitis, atopic, 7 12.1

Graphical network of the top 20 diseases related to Dermatitis:



Diseases related to Dermatitis
Sources

Symptoms & Phenotypes for Dermatitis

About this section

UMLS symptoms related to Dermatitis:


exanthema, pruritus

GenomeRNAi Phenotypes related to Dermatitis according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.55 MSMO1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.55 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.55 IL13
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.55 IL13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.55 MSMO1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.55 MSMO1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.55 NACA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.55 MSMO1 NACA FAF2 IL13
9 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.55 MSMO1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.55 NACA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.55 IL13
12 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.55 MSMO1 FAF2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.55 NACA

MGI Mouse Phenotypes related to Dermatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.32 IL4 NOD2 TSLP CARD11 CCL11 CCL17
Sources

Drugs & Therapeutics for Dermatitis

About this section

PubMedHealth treatment related to Dermatitis: 63

Eczema is a chronic condition. Treatment cannot cure it, but regular skin care and medication can help to keep the itching and rash at bay. The main treatment options are:Basic treatment: Lipid-replenishing and moisturizing products (emollients) are generously applied to the skin at least twice a day to keep it from drying out. This can help relieve itching and protect the skin from germs and irritants.Special soaps, liquid cleansers and shampoos: Normal soaps and products like shampoo or shower gel contain various substances that can dry out your skin. Special cleansing products without these substances are available to get around this problem. But basic treatment with emollients can usually compensate for the loss of moisture caused by normal soaps.Steroid creams: Eczema flare-ups are usually treated with steroid creams because they can relieve the itching and inflammation. They are typically used only for acute symptoms. But they are sometimes used at regular intervals together with moisturizing skin care products (basic treatment): for example, as a "weekend treatment" where a steroid cream is applied on one or two days a week.Pimecrolimus and tacrolimus: Pimecrolimus and tacrolimus are two other medicines that can be used to treat eczema. They are not approved for use in children under the age of two years, though. These two medicines are also applied to the skin in a cream or ointment, and can be used if steroid products are not an option. This might be the case if steroid treatment is not tolerated or is ineffective. Pimecrolimus and tacrolimus may also be an option for long-term treatment of sensitive skin in the face and neck area. They can also be used on one or two days per week only, as described above.Other eczema treatment options include wet wraps, UV radiation and medications that suppress certain immune responses. Tablets containing these medicines are used if other treatments don't work, or if the eczema is very severe or affects large areas of skin. Because they have an effect throughout the entire body, they may have more extensive side effects than topical treatments.Allergy medications (antihistamines) are also commonly used to relieve itching. But research has now shown that they are not suitable for treating eczema, whether used as tablets or a cream.People often try out herbal products or dietary supplements, such as evening primrose oil, borage oil, vitamin B6, vitamin E and zinc. But research hasn't shown that these products are effective.Many other treatments such as laser therapies or hyposensitization have not yet been studied enough, so they are not recommended by medical associations.

Drugs for Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
2
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
3
Zinc oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 1314-13-2
4
Montelukast Approved Phase 4,Not Applicable 158966-92-8 5281040
5
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable 64-17-5 702
6
Petrolatum Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 8009-03-8
7 Titanium dioxide Approved Phase 4,Not Applicable 13463-67-7
8
Bacitracin Approved, Vet_approved Phase 4,Phase 3,Phase 2 1405-87-4 439542 10909430
9
Bronopol Approved Phase 4,Phase 3,Phase 2 52-51-7
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
11 Parthenolide Approved, Investigational Phase 4,Phase 3,Phase 2 20554-84-1
12
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
13
Isotretinoin Approved Phase 4,Phase 3,Not Applicable 4759-48-2 5538 5282379
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
15
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Not Applicable 69-72-7 338
16
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
17
Glycerol Approved, Investigational Phase 4,Phase 3,Not Applicable 56-81-5 753
18
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
19
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
20
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
21
Desonide Approved, Investigational Phase 4,Phase 3,Not Applicable 638-94-8 5311066
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
25
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8
26
Loratadine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 79794-75-5 3957
27
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 378-44-9 9782
28
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
29
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
30
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
31
Desoximetasone Approved Phase 4 382-67-2 5311067
32
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137071-32-0 6447131 17753757
33
Fluocinonide Approved, Investigational Phase 4,Not Applicable 356-12-7 9642
34
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3 90566-53-3 62924
35
Cortisone acetate Approved, Investigational Phase 4,Phase 2 1950-04-4, 50-04-4 5745
36
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 83881-51-0 2678
37
Levocetirizine Approved Phase 4,Phase 3,Phase 1 130018-77-8 1549000
38
Ketoconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 65277-42-1 47576 3823
39
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 1 242138-07-4
40
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
41
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
42
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
43
Adapalene Approved Phase 4,Phase 2,Phase 1 106685-40-9 60164
44
Benzoyl peroxide Approved Phase 4 94-36-0 7187
45
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
46
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
47
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
48
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
49
Adalimumab Approved Phase 4,Phase 2 331731-18-1 16219006
50
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662

Interventional clinical trials:

(show top 50) (show all 1292)
# Name Status NCT ID Phase Drugs
1 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
2 Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children? Unknown status NCT02534467 Phase 4 Montelukast
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
5 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
6 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
7 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
8 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
9 Quaternium-15, Use Test Unknown status NCT00311454 Phase 4 T.R.U.E.Test
10 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
11 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
12 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
13 Evaluating Treatment Resistant Dermatitis TaroIIR Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
14 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
15 A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
16 An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis Completed NCT01828879 Phase 4 Tacrolimus
17 An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis Completed NCT01782729 Phase 4 Tacrolimus
18 Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
19 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
20 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
21 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
22 Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis Completed NCT01591070 Phase 4 Tacrolimus;Tacrolimus
23 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
24 Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Completed NCT01323673 Phase 4 clobetasol propionate 0.05%;Vehicle / Placebo
25 Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
26 A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
27 Epiceramâ„¢ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
28 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
29 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
30 A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis Completed NCT00568412 Phase 4 Elidel
31 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
32 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
33 Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
34 Elidel-Study: Elidel in Patients With Atopic Dermatitis Completed NCT00180141 Phase 4 Elidel-Creme
35 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
36 Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
37 Combination Therapy for Atopic Dermatitis Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
38 Management of Pruritus With Xyzal in Atopic Dermatitis Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
39 Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
40 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
41 Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children Completed NCT02519556 Phase 4 Probiatop;Placebo
42 Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis Completed NCT02589392 Phase 4
43 Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis Completed NCT00673725 Phase 4 Locobase® REPAIR
44 Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis Completed NCT01745159 Phase 4 tacrolimus
45 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
46 A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis Completed NCT01065714 Phase 4 Hydrogel vehicle;Eucerin Lotion
47 STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% Completed NCT00703846 Phase 4 Ketoconazole
48 Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients Completed NCT00822783 Phase 4 Omalizumab;Placebo
49 A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
50 Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis Completed NCT00828464 Phase 4 clobetasol propionate

Search NIH Clinical Center for Dermatitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dermatitis

Sources

Genetic Tests for Dermatitis

About this section

Genetic tests related to Dermatitis:

# Genetic test Affiliating Genes
1 Eczema 29
Sources

Anatomical Context for Dermatitis

About this section

MalaCards organs/tissues related to Dermatitis:

41
Skin, Testes, Breast, T Cells, Colon, Neutrophil, Eye
Sources

Publications for Dermatitis

About this section

Articles related to Dermatitis:

(show top 50) (show all 6239)
# Title Authors Year
1
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
2
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with SevereA Itch. ( 29317264 )
2018
3
Pathogenicity of blood orf virus isolates in the development of dairy goat contagious pustular dermatitis. ( 29778194 )
2018
4
Malassezia species retrieved from skin with pityriasis versicolor, seborrhoeic dermatitis and skin free of lesions: a comparison of two sampling methods. ( 29505089 )
2018
5
Allergic contact dermatitis caused by octylisothiazolinone in a leather sofa. ( 29790173 )
2018
6
Textile contact dermatitis caused by octylisothiazolinone in compression stockings. ( 29399813 )
2018
7
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
8
Chemokine Signaling in Allergic Contact Dermatitis: Toward Targeted Therapies. ( 29939854 )
2018
9
Pityriasis rubra pilaris: a rare inflammatory dermatosis. ( 29440245 )
2018
10
Allergic contact dermatitis caused by acrylic-based medical dressings and adhesives. ( 29888412 )
2018
11
Increased interleukin-36I^ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/SAczary syndrome. ( 29314201 )
2018
12
A 8-year population-based cohort study of irritable bowel syndrome in childhood with history of atopic dermatitis. ( 29374025 )
2018
13
Declining prevalence of allergic contact dermatitis caused by tosylamide formaldehyde resin in nail polish. ( 29726606 )
2018
14
Validation of patient-reported global severity of atopic dermatitis in adults. ( 28905999 )
2018
15
Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study. ( 29343261 )
2018
16
Expression of Elafin in Dermatitis Herpetiformis. ( 29293478 )
2018
17
Why now? Delayed drug-induced pancreatitis due to dapsone for dermatitis herpetiformis. ( 29915658 )
2018
18
Identification and interaction analysis of key genes and microRNAs in atopic dermatitis by bioinformatics analysis. ( 29974487 )
2018
19
Chronic Nasolabial Fold Seborrheic Dermatitis Successfully Controlled With Crisaborole. ( 29742192 )
2018
20
Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. ( 29496465 )
2018
21
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. ( 29966024 )
2018
22
Bilateral Periorbital Impetigo Inducing Significant Dermatitis and Cicatricial Eyelid Changes in an Adult. ( 29784090 )
2018
23
Treatment of seborrheic dermatitis: a comprehensive review. ( 29737895 )
2018
24
Novel association of a papuloerythroderma of Ofuji phenotype with dermatitis herpetiformis. ( 29664108 )
2018
25
Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations. ( 29971775 )
2018
26
Breast abscess caused by <i>Staphylococcus aureus</i> in 2 adolescent girls with atopic dermatitis. ( 29963104 )
2018
27
Pesticide contact dermatitis in agricultural workers of Himachal Pradesh (India). ( 29974480 )
2018
28
Phloxine O, a Cosmetic Colorant, Suppresses the Expression of Thymic Stromal Lymphopoietin and Acute Dermatitis Symptoms in Mice. ( 29310423 )
2018
29
An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. ( 29676446 )
2018
30
IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy and atopic dermatitis. ( 29380876 )
2018
31
Allergic contact dermatitis resulting from cetyl PEG/PPG-10/1 dimethicone in a deodorant cream. ( 29430705 )
2018
32
Impact of dupilumab on health-related quality of life in patients with atopic dermatitis. ( 29441557 )
2018
33
Analysis of Bacterial and Fungal Nucleic Acid in Canine Sterile Granulomatous and Pyogranulomatous Dermatitis and Panniculitis. ( 29145794 )
2018
34
Psoriasis-like Dermatitis in Adulthood: a Skin Manifestation of Holocarboxylase Synthetase Deficiency. ( 29701239 )
2018
35
Enolase-1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes. ( 29430682 )
2018
36
Self-Reported Fractures in Dermatitis Herpetiformis Compared to Coeliac Disease. ( 29538319 )
2018
37
Fecal Microbiome and Food Allergy in Pediatric Atopic Dermatitis: A Cross-Sectional Pilot Study. ( 29393195 )
2018
38
Online education improves pediatric residents' understanding of atopic dermatitis. ( 29193379 )
2018
39
Pediatric &amp;quot;pet consort dermatitis&amp;quot;-Allergic contact dermatitis from transfer of bronopol from a pet cat. ( 29943851 )
2018
40
Allergic contact dermatitis caused by hydroxyacetophenone in a face cream. ( 29341188 )
2018
41
Cause-specific mortality in adults with atopic dermatitis. ( 29102489 )
2018
42
Prognosis of Dermatitis Herpetiformis Patients with and without Villous Atrophy at Diagnosis. ( 29783727 )
2018
43
Autoimmune Progesterone Dermatitis. ( 29692467 )
2018
44
Dermatitis, Herpetiformis ( 29630215 )
2018
45
Photoallergic dermatitis associated with fixed-dose combination of antiretroviral agent (abacavir-lamivudine-dolutegravir). ( 29851666 )
2018
46
Associations of TAP1 genetic polymorphisms with atopic diseases: asthma, rhinitis and dermatitis. ( 29416713 )
2018
47
Systemic allergic dermatitis caused by sodium metabisulfite in rectal enemas. ( 29446100 )
2018
48
Allergic contact dermatitis caused by triethylenetetramine: the glue is the clue. ( 29392782 )
2018
49
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. ( 29528923 )
2018
50
Atopic dermatitis in Chinese patients shows T<sub>H</sub>2/T<sub>H</sub>17-skewing with psoriasiform features. ( 29964056 )
2018
Sources

Variations for Dermatitis

About this section

ClinVar genetic disease variations for Dermatitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XX;t(7;13)(p13;q34)dn Translocation Pathogenic
2 46;X;t(X;12)(p11.2;q24.33)dn Translocation Likely pathogenic
3 46;XY;t(16;20)(q23.1;p11.22) Translocation Uncertain significance
4 46;XY;t(2;17)(p25;q23)dn Translocation Pathogenic
5 46;XY;t(1;4)(q32;q11) Translocation Uncertain significance
Sources

Expression for Dermatitis

About this section
Search GEO for disease gene expression data for Dermatitis.
Sources

Pathways for Dermatitis

About this section

Pathways related to Dermatitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.86 CARD11 CCL11 CCL22 DSG1 FAF2 IGHE
2
PEDF Induced Signaling 64
Show member pathways
 13.47 CCL11 CCL17 CCL22 CCL27 IL13 IL31
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.14 CCL11 CCL22 IGHE IL13 IL31 IL31RA
4
IL-17 Family Signaling Pathways 65
Show member pathways
 12.13 CCL11 CCL17 IL13 IL4
5
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.81 CCL11 CCL17 CCL22 CCL27 IL13 IL4
6
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 11.73 CCL11 CCL17 CCL22 CCL27
7
Innate Lymphoid Cell Differentiation Pathways 65
11.59 IL13 IL4 TSLP
8
Interleukin-4 and 13 signaling 66
11.41 CCL11 CCL22 IGHE IL13 IL4
9
IL4-mediated signaling events 1
11.36 CCL11 CCL17 IGHE IL4
10
Interleukin-10 signaling 66
11.32 CCL22 IL13 IL4
11
Lung fibrosis 1
11.26 CCL11 CMA1 IL13 IL4
12
Development and heterogeneity of the ILC family 1
11.09 IL13 IL4 TSLP
13
Th2 Differentiation Pathway 65
10.76 CCL11 CCL17 CCL22 IL13 IL31 IL4
Sources

GO Terms for Dermatitis

About this section

Cellular components related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CCL11 CCL17 CCL22 CCL27 CMA1 IL13
2 extracellular region GO:0005576 9.36 CCL11 CCL17 CCL22 CCL27 CMA1 FAF2

Biological processes related to Dermatitis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CCL11 CCL17 CCL22 IL13 NOD2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 CCL11 CCL17 CCL22 NOD2
3 chemotaxis GO:0006935 9.76 CCL11 CCL17 CCL22 CCL27
4 cellular response to tumor necrosis factor GO:0071356 9.75 CCL11 CCL17 CCL22
5 cellular response to interferon-gamma GO:0071346 9.74 CCL11 CCL17 CCL22
6 cellular response to interleukin-1 GO:0071347 9.72 CCL11 CCL17 CCL22
7 chemokine-mediated signaling pathway GO:0070098 9.71 CCL11 CCL17 CCL22
8 cytokine-mediated signaling pathway GO:0019221 9.7 CCL11 CCL22 IGHE IL13 IL31 IL31RA
9 neutrophil chemotaxis GO:0030593 9.69 CCL11 CCL17 CCL22
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IL13 IL31RA TSLP
11 monocyte chemotaxis GO:0002548 9.61 CCL11 CCL17 CCL22
12 positive regulation of B cell proliferation GO:0030890 9.58 CARD11 IL13 IL4
13 immune response GO:0006955 9.56 CCL11 CCL17 CCL22 CCL27 CMA1 IGHE
14 lymphocyte chemotaxis GO:0048247 9.54 CCL11 CCL17 CCL22
15 positive regulation of interleukin-13 production GO:0032736 9.52 IL4 TSLP
16 T-helper 2 cell cytokine production GO:0035745 9.32 IL31RA IL4
17 negative regulation of complement-dependent cytotoxicity GO:1903660 9.26 IL13 IL4
18 regulation of signaling receptor activity GO:0010469 9.23 CCL11 CCL17 CCL22 CCL27 IL13 IL31

Molecular functions related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.43 CCL11 CCL17 CCL22
2 CARD domain binding GO:0050700 9.37 CARD11 NOD2
3 cytokine receptor binding GO:0005126 9.33 IL13 IL31 IL4
4 CCR3 chemokine receptor binding GO:0031728 9.32 CCL11 CCL27
5 chemokine activity GO:0008009 9.26 CCL11 CCL17 CCL22 CCL27
6 cytokine activity GO:0005125 9.17 CCL11 CCL17 CCL22 IL13 IL31 IL4
Sources

Sources for Dermatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....